# Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea

> **NCT05944965** · PHASE1,PHASE2 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 27 (actual)

## Conditions studied

- OSA

## Interventions

- **DRUG:** Atomoxetine 80 mg plus Oxybutynin 5 mg
- **DRUG:** Atomoxetine 80 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05944965
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-01
- **Primary completion:** 2025-06-17
- **Final completion:** 2025-06-17
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05944965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05944965, "Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05944965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*